Compare AstraZeneca plc (AZN) vs Baker Hughes Co (BKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Baker Hughes Co — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while Baker Hughes Co trades at $57.26 (market cap $57.32B). The key difference: AstraZeneca plc is far larger — about 4.4× Baker Hughes Co's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | BKR | |
|---|---|---|
Market Cap | $253.13B | $57.32B |
Sector | Health | Energy |
52-Week High | $209.48 | $69.67 |
52-Week Low | $137.44 | $38.68 |
Enterprise Value | $279.37B | $58.72B |
Dividend Yield | 1.92% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Baker Hughes (BKR) trades at $57.66, up 0.17% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 66.7% buy rating from analysts, alongside a $74.09 price target, highlight positive momentum. The company secured key LNG and power infrastructure contracts, supporting growth in energy transition markets. Operating cash flow remains robust at $3.81B for 2025, though net income dipped slightly to $2.59B.
Outlook is positive driven by LNG expansion and AI-powered energy demand, but risks include oil price volatility and integration challenges from the Chart Industries acquisition. Valuation metrics like a P/E of 18.42 and ROE of 17.14% suggest reasonable pricing for growth prospects, though execution on new contracts is critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
